...we evaluated the efficacy of sapanisertib in patients with treatment-refractory metastatic renal cell carcinoma...Diminished or loss of PTEN expression by immunohistochemistry was seen in 8 of 21 patients and trended toward shorter PFS compared with intact PTEN (median 1.9 v 3.7 months; hazard ratio 2.5; 95% CI, 0.9 to 6.7; P = .055)....Sapanisertib had minimal activity in treatment-refractory mRCC independent of mTOR pathway alterations.